Olon SpA, a provider of active pharmaceutical ingredient (API) contract development and manufacturing services and a generics supplier, has acquired Capua BioServices SpA, a global provider of contract development and manufacturing services in the field of microbial fermentation.
 
“By acquiring Capua BioServices, Olon will have the opportunity to accelerate growth by adding new CDMO projects and to be recognized as European leader in the CDMO of microbial fermentation with a total fermentation capacity of 4,500 m3,” said Paolo Tubertini, chief executive officer, Olon. “Capua comes with a world-class manufacturing facility and a dedicated team of experts that will support us in delivering high-quality services that meet or exceed customer expectations.
 
“Following the acquisition of Ricerca Biosciences’ chemical division in mid-2017 and the manufacturing site in Mahad, India, announced in Q3 2018 with closing in Q1 2019, we have now completed a further step in our strategic plan. With this acquisition Olon has successfully finalized its 3-year development plan.”
 
Capua BioServices is a global provider of services in the field of custom microbial process development and manufacturing. It offers dedicated solutions for proteins, specialty small molecules and microorganisms for applications in pharma, food, feed and other bio-industrial markets. The site is beta-lactam free with a total fermentation capacity of about 1,400 m3, located in Capua, nearby Naples (South of Italy) with approximately 230 employees. Over the past 60 years, the company has built a track record based on extensive experience in working with a variety of bacterial, yeast and fungal systems. No impact on jobs is planned and Olon intends to invest in the site and pursue business development opportunities to optimize the plant’s utilization and expand its customer base.